



Theraclion Continues Its International Expansion with Asia Branch Opening and New Hires in Europe

Malakoff, FRANCE – March 12, 2015 – THERACLION (Alternext, FR0010120402 - ALTHE) a company specializing in leading-edge medical equipment for echotherapy, today announces the opening of an office in Hong Kong, People’s Republic of China, that will serve as Theraclion’s Asia Branch as well as the addition of strategic hires throughout Europe.

The greatest number of procedures for breast fibroadenomas and thyroid nodules takes place in Asia, making it a key focus region for Theraclion. In China alone, 1.2 million patients are diagnosed with fibroadenomas each year, 60 percent of whom receive treatment. Up to 40 percent of the adult population has evidence of thyroid nodules, among whom a large proportion undergoes thyroidectomy.

“Opening a branch in Hong Kong provides a central location, allowing us to develop our business in South East Asia and Mainland China while providing the highest level of service for our future customers and partners,” says Sylvain Yon, Theraclion Deputy CEO.

In addition to the opening of a new office in Asia, Theraclion has appointed a new Business Development Director for Italy and Southern Europe. Giuliano Laghi joined Theraclion earlier this year as Vice President for Italy & Southern Europe. He will oversee the company’s business development in Italy, a key target in Theraclion’s European growth strategy.

Laghi began his career in the medical field in 1998 at Johnson & Johnson, where he held several positions in sales, marketing and development of radiofrequency (RF) and ultrasound products in the field of surgical technology. From 2010 to 2014, Laghi was Sales and Marketing Director of the Italian diagnostic ultrasound division of Toshiba. He graduated with a major in Math from the Alma Mater Studiorum University of Bologna, Italy.

Additionally, Theraclion has hired two sales agents in Switzerland and Finland to further strengthen the company’s presence across Europe.

“The opening of our Asia branch and the addition of strategic hires throughout Europe are important steps in our expansion in these key markets. We remain focused on accelerating global adoption of echotherapy as a non-invasive alternative to surgery for patients looking for breast fibroadenoma or thyroid nodule treatment without the consequences of a surgical intervention,” says David Caumartin, CEO of Theraclion.

About Theraclion

Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on leading-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound.

Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France, Theraclion has brought together a team of 23 people, 65 percent of whom are dedicated to R&D and clinical trials. For more information, please visit Theraclion's website: www.theraclion.com.

Theraclion is listed on Alternext Paris

Mnemonic: ALTHE - ISIN Code: FR0010120402



Contacts:

Theraclion

David Caumartin

CEO

Phone: +33 (0)1 55 48 90 70

david.caumartin@theraclion.com

NewCap

Financial Communications & Investor Relations

Emmanuel Huynh / Sophie Boulila

Phone: +33 (0)1 44 71 94 91

theraclion@newcap.fr

ALIZE RP

Press relations

Caroline Carmagnol / Valentine Boivin

Phone: + 33 (0)1 44 54 36 63

theraclion@alizerp.com